SCHEDULE 13G/A: Institutional Investors Disclose 4.9% Passive Stake in Silexion Therapeutics

CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.9% in Silexion Therapeutics Corp. ordinary shares.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (acting as investment manager for CVI Investments, Inc.) collectively report beneficial ownership of 456,531 ordinary shares of Silexion Therapeutics Corp.
• This ownership represents 4.9% of the company's ordinary shares outstanding, based on 8,692,392 shares outstanding as of March 31, 2025.
• The reported shares are issuable upon the exercise of warrants.
• The warrants include a contractual limitation preventing their exercise if it would result in the Reporting Persons' beneficial ownership exceeding 4.99% of the class.
• This filing is an Amendment No. 1 to a previously filed Schedule 13G, updating their reported ownership position.

Sentiment

Score: 6

Explanation: The document is a neutral, factual disclosure of beneficial ownership. It indicates a significant, albeit passive, institutional investment, which can be viewed positively as a vote of confidence, but provides no operational or financial performance details to assess overall sentiment.

Positives

• The filing indicates a significant, albeit passive, investment by institutional entities (CVI Investments, Inc. and Heights Capital Management, Inc.) in Silexion Therapeutics Corp.
• The beneficial ownership is maintained below the 5% threshold, consistent with a passive investment intent under Rule 13d-1(b), avoiding the more stringent reporting requirements of a Schedule 13D.

Risks

• The beneficial ownership reported is primarily derived from warrants, which are subject to an exercise limitation preventing the Reporting Persons from exceeding 4.99% beneficial ownership of Silexion Therapeutics Corp. shares, potentially limiting their ability to increase their stake rapidly.

Future Outlook

The document is a beneficial ownership report and does not provide forward-looking statements or guidance regarding Silexion Therapeutics Corp.'s future operations or financial performance.

Management Comments

• The filing includes a certification from the Reporting Persons stating that the securities were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This Schedule 13G filing reflects a routine disclosure of passive institutional investment in a publicly traded company. Such filings are common and provide transparency regarding significant ownership stakes, particularly those below the 5% threshold that would trigger more active reporting requirements (Schedule 13D).

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves a regulatory compliance purpose by disclosing passive beneficial ownership.
• It does not contain performance metrics or operational data that would allow for a direct comparison to industry-specific financial or operational standards or specific comparable companies/projects.
• The 4.9% stake is just below the 5% threshold that would require a Schedule 13D filing, indicating a passive investment strategy consistent with many institutional investors who prefer not to be deemed activist.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive institutional ownership, which can influence market perception and liquidity.
• Company Management: Awareness of a significant passive investor, though without direct influence on control.

Next Steps

• The document does not specify any future actions, events, or milestones for Silexion Therapeutics Corp. or the Reporting Persons beyond the ongoing passive investment.

Key Dates

Keywords

Silexion Therapeutics Corp, CVI Investments Inc, Heights Capital Management Inc, Schedule 13G, beneficial ownership, ordinary shares, warrants, institutional investment, passive investment